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a b s t r a c t
Aim: To assess the impact of combined treatment with simvastatin and ezetimibe or
treatment with simvastatin only on lipoprotein-associated phospholipase A2 mass level
in patients with coronary heart disease.
Methods: One hundred patients with angiographically documented coronary atherosclerosis
took part in the investigation. Lp-PLA2 mass level and cholesterol fractions were determined
at baseline and after 6 months of treatment. Lp-PLA2 mass was determined by PLAC Test;
DiaDexus, Inc.
Results: Combined treatment with ezetimibe and simvastatin led to signiﬁcantly greater
declines in Lp-PLA2 and lipid proﬁle compared with treatment only with simvastatin
(P < 0.05). Combination therapy with ezetimibe and simvastatin  20 mg/day proved to be
as effective as monotherapy with simvastatin 80 mg/day on the effect on Lp-PLA2 mass
level and lipids (P < 0.05). Lp-PLA2 mass level was initially higher in patients with
three-vessel coronary artery disease, compared with patients with one-vessel coronary
artery disease while baseline levels of lipids and hs-CRP did not differ signiﬁcantly.
Conclusions: Combined treatment, using half the dose of simvastatin, led to greater reduc-
tion of Lp-PLA2 mass level total cholesterol and LDL-C, compared to monotherapy with
simvastatin. Due to the steady decline of target levels of LDL-C, which leads to prescribing
high doses of statins (and it is not always possible because of the presence of co-morbidities),
combination therapy with statin and ezetimibe is a reliable alternative, which allows not
only to largely reduce LDL-C but also to signiﬁcantly reduce such important participants of
atherosclerosis process and markers of inﬂammation, as Lp-PLA2 and CRP.
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One of the key factors in the development of atherosclerosis
is a chronic systemic inﬂammation with local speciﬁc
manifestations in the intima of the vessels. Inﬂammation
plays a major role in the genesis and progression of
atherosclerotic plaques, its evolution in the vulnerable
plaque rupture and loosening tire [1]. In recent years,
lipoprotein-associated phospholipase A2 (Lp-PLA2), which
is a marker of intravascular inﬂammation, has attracted the
attention of scientists. Numerous studies have demonstrat-
ed the role of Lp-PLA2 as a risk factor for cardiovascular
disease and a direct participant in the development and
progression of atherosclerosis.
Lp-PLA2 is associated mainly with low-density lipoproteins
(LDL), whereas a small proportion of circulating enzyme is also
associated with high-density lipoproteins (HDL) and lipopro-
tein-a. Mechanistically, Lp-PLA2 hydrolyzes oxidatively al-
tered phospholipids that have shortened sn2 fatty acids to
produce oxidized fatty acids and lysophosphatidylcholine, a
function that deems Lp-PLA2, a pro-atherogenic agent [2–5].
Increased Lp-PLA2 testiﬁes not only to coronary artery disease
[6], but also can further deﬁne prognosis and the risk of
vascular complications [6–16]. Lp-PLA2 reﬂects the presence
and intensity of intravascular inﬂammation, the marker of
which it is.
Using the classic risk factors cannot account for all cases of
coronary events in patients with normal lipid proﬁle [17]. That
is why, the FDA approved a deﬁnition Lp-PLA2 as a screening
test that predicts a patient's risk for future CHD events. ACC/
AHA and ESC have recommended Lp-PLA2 deﬁnition for
asymptomatic or moderate and high risk patients to clarify the
risks and to decide beginning or increasing the lipid-lowering
therapy [18–21].
The ability to inﬂuence on intravascular inﬂammation
(Lp-PLA2) as well as on non-speciﬁc inﬂammation (hs-CRP)
relates to the pleiotropic effects of statins, and it is realized,
sometimes, regardless of the lipid-lowering effect of statins.
Information that hypolipidemic drugs, particularly statins,
reduce the level of Lp-PLA2 suggests that Lp-PLA2 can be
considered as a target for the therapy action to suppressFig. 1 – Distribution simvastatin doses in coinﬂammatory processes and achieve stabilization of athero-
sclerotic plaque formation [22]. It has been shown that statins
– pravastatin, atorvastatin, rosuvastatin and simvastatin –
signiﬁcantly lowered Lp-PLA2 levels [22–35], but is it possible
for combination therapy: ezetimibe with lower doses of
statins? As a powerful lipid-lowering effect of the combination
of ezetimibe and a statin is known, our aim was to evaluate the
possibility of reducing the intravascular inﬂammation using
combination therapy with a lower dose of the statin.
Materials and methods
One hundred patients with angiographically documented
coronary atherosclerosis took part in the investigation. All
patients included in the study, even with previously estab-
lished CHD, had not taken lipid-lowering drugs for at least 6
months before inclusion in the study. Patients were randomly
assigned into two treatment groups: a group of active
treatment (combination therapy group) took ezetimibe
10 mg/day in combination with simvastatin, and the control
group (group monotherapy) took simvastatin only. The
distribution of patients in the two treatment groups was
performed by using envelopes. No other randomization
criteria were used. The distribution of patients did not
inﬂuence the results of the previous coronary angiography
or the lipid proﬁle. The results of coronary angiography were
used to conﬁrm the presence of CHD and in more detail were
evaluated after enrollment.
The initial dose of simvastatin in all patients included in
the study was 20 mg/day, regardless of the chosen strategy of
therapy (monotherapy group or combination treatment
group). The dose of simvastatin was titrated up to 40 or
80 mg/day every 6 weeks, if it was necessary, according to the
achievement of the target level of LDL-C <2.5 mmol/L. After
achieving the target level of LDL-C and conﬁrming measure-
ments, the dose of simvastatin was unchanged for 6 months
(until the end of the study). Simvastatin dose titration results
are shown in Fig. 1.
The study excluded patients with acute coronary syn-
drome, myocardial infarction, which are less than 6 months,
family hyperlipidemia, severe liver disease and kidneymbination therapy and monotherapy.









Age (years) 61 [54; 65] 62 [56; 69] 0.24*
Female (%) 22% 26% 0.81**
BMI (kg/m2) 26 [25; 30] 27.5 [26; 31] 0.12*
Current smoking (%) 52% 70% 0.15**
Family history of CAD (%) 66% 80% 0.18**
Diabetes (%) 14% 14% 1**
History of AMI (%) 48% 60% 0.31**
Hypertension (%) 90% 94% 0.71**
Angiography
One-vessel CAD (n = 26) 30% 22% 0.49**
Two-vessel CAD (n = 38) 32% 44% 0.30**
Three-vessel CAD (n = 36) 38% 34% 0.83**
Medication use (%)
Platelet inhibitor (%) 100% 100% 1**
Beta-blocker (%) 96% 100% >0.1**
RAAS (%) 90% 86% >0.1**
Previous lipid-lowering therapy None None
Simvastatin dose in the study (median) (mg/day) 40 [40; 80] 20 [20; 40] <0.001*
Simvastatin dose in the study (mean dose) (mg/day) 54.4 27.6 <0.001*
* Mann–Whitney U test.
** Two-tailed Fisher's exact test.
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diseases. There were no signiﬁcant differences between
groups in age, gender, body mass index, risk factors,
comorbidity, severity of angina, the severity of coronary
lesions and conducted concomitant therapy. More detailed
characteristics of patients are presented in Table 1.
Lp-PLA2 mass level, hs-CRP and cholesterol fractions were
determined at baseline and after 6 months of treatment. Lp-
PLA2 mass was determined by use of a dual monoclonal
antibody immunoassay standardized to recombinant Lp-PLA2
(PLAC Test; DiaDexus, Inc.) [2,36]. High sensitivity C-reactive
protein was determined by automated analyzer nephelomet-
ric method by measuring side scattering of laser radiation at a
wavelength of 840 nm.
Blood samples for determining Lp-PLA2 mass level and hs-
CRP, which was taken at the beginning of the study and at the
ﬁnal stage, have been kept for 1.5 years in temperature below
70 8C. Then we measured Lp-PLA2: the blood samples from
one patient were determined using the same test kit (for
doublets too).
Statistical processing of the results of the study was carried
out in accordance with standard methods of statistics.
Statistical analysis was performed using STATISTICA 6.0
softpack. Data are presented as the median and range. To test
the normality of the distribution of quantitative traits, we
used the Shapiro–Wilk test. The signiﬁcance of differences of
all parameters of quantitative traits was determined using
paired and unpaired analysis methods for nonparametric
variables by Mann–Whitney U test for independent groups
and Wilcoxon matched pairs test for dependent parameters.
The signiﬁcance of differences parameters qualitative char-
acteristics was assessed using two-tailed Fisher's exact test.
To assess the relationship of quantitative traits Spearman'sRank Order Correlation was used. For all types of analysis
statistically signiﬁcant differences at P values <0.05 were
considered.
Results
All included patients have completed the study, with 50
persons in each group.
In both groups, Lp-PLA2 mass level has exceeded the
physiological level (>200 ng/ml) in 98% of the cases, while
median Lp-PLA2 mass level was equal to 351.89 ng/ml and
352.97 ng/ml in the combination and monotherapy treatment
group, respectively. The median concentration of hs-CRP for
combination therapy group was 2.62 mg/L, and for mono-
therapy group it was 1.63 mg/L.
Dynamics of lipid proﬁle and inﬂammatory markers on
combined therapy with simvastatin and ezetimibe
In patients treated with simvastatin and ezetimibe, Lp-PLA2
mass level signiﬁcantly decreased by 45% after 6 months of
treatment (from 351.89 [286.6, 440.1] ng/ml to 200.95 [173.8,
223.7] ng/ml, P < 0.001). hs-CRP level was also signiﬁcantly
reduced by 37% after 6 months of treatment (from 2.62 [1.3,
4.5] mg/L to 0.96 [0.5, 3.5] mg/L, P < 0.001). Combined therapy
with simvastatin and ezetimibe led to a signiﬁcant reduction
in total cholesterol by 35% (from 5.95 [5.4; 6.8] mmol/L to 3.85
[3.4, 4.3] mmol/L, P < 0.001) and LDL-C by 50% (from 4.02 [3.4,
4.8] mmol/L to 2.16 [1.8, 2.4] mmol/L, P < 0.001); TG by 23%
(from 1.52 [1.2, 2.0] mmol/L to 1.11 [0.9, 1.7] mmol/L, P < 0.001)
after 6 months of therapy compared with the baseline
(Table 2).
Table 2 – Effect of the combination therapy with simvastatin and ezetimibe on cholesterol levels and inflammatory
markers.
Parameter Baseline Posttreatment P* D%
Lp-PLA2 (ng/ml) 351.89 [286.6; 440.1] 200.95 [173.8; 223.7] <0.001 45
hs-CRP (mg/L) 2.62 [1.3; 4.5] 0.96 [0.47; 3.54] <0.001 37
Total cholesterol (mmol/L) 5.95 [5.4; 6.8] 3.85 [3.4; 4.3] <0.001 35
LDL-C (mmol/L) 4.02 [3.4; 4.8] 2.16 [1.8; 2.4] <0.001 50
HDL-C (mmol/L) 1.15 [0.9; 1.3] 1.13 [1.0; 1.3] 0.920 1
TG (mmol/L) 1.52 [1.2; 2.0] 1.11 [0.9; 1.7] <0.001 23
* Wilcoxon matched pairs test. Represents median levels and interquartile range.
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simvastatin monotherapy
In the monotherapy group, Lp-PLA2 mass level and lipid proﬁle
have also signiﬁcantly decreased. Lp-PLA2 mass level has
reduced by 38% (from 352.97 [272.4, 401.7] ng/ml to 213.08
[192.2, 235.3] ng/ml, P < 0.001). hs-CRP level has reduced by
48% (from 1.63 [1.2, 3.2] mg/L to 0.69 [0.29, 2.0] mg/L, P < 0.001).
Total cholesterol has decreased by 28% (from 5.64 [5.2, 6.1]
mmol/L to 4.01 [3.7, 4.3] mmol/L, P < 0.001), LDL-C has
decreased by 40% (from 3.68 [3.0, 4.1] mmol/L to 2.19 [2.1,
2.4] mmol/L, P < 0.001), and TG has decreased by 17% (from 1.5
[1.1; 1.9] mmol/L to 1.12 [0.9, 1.7] mmol/L, P = 0.002) after 6
months of therapy (Table 3).
When comparing the two tactics lipid-lowering therapy
has revealed that the Lp-PLA2 mass level, total cholesterol
and LDL-C levels decreased to a greater extent in the
combination therapy group than in the monotherapy group.
The Lp-PLA2 mass level reduction was 45% in the combination
treatment group versus 38% in the monotherapy group
(P = 0.03). Total cholesterol decreased by 35% in the combina-
tion treatment group versus 28% in the monotherapy group
(P = 0.003).
LDL-C reduction was 50% in the combination treatment
group versus 40% in the monotherapy group (P < 0.001). With
regard to hs-CRP, none of the tactics lipid-lowering therapy
showed any beneﬁts, and the results of treatment were
comparable (P > 0.05).
Effect of combination therapy with simvastatin and ezetimibe
on lipid proﬁle and Lp-PLA2 mass level, according to the
simvastatin doses included in the combination
No statistically signiﬁcant differences were observed on the
effect on Lp-PLA2 mass level and lipid proﬁle between
different doses of simvastatin (20 or 40 mg/day) in theTable 3 – Effect of the monotherapy with simvastatin on chole
Parameter Baseline 
Lp-PLA2 (ng/ml) 352.97 [272.4; 401.7] 
hs-CRP (mg/L) 1.63 [1.2; 3.2] 
Total cholesterol (mmol/L) 5.64 [5.2; 6.1] 
LDL-C (mmol/L) 3.68 [3.0; 4.1] 
HDL-C (mmol/L) 1.28 [1.1; 1.4] 
TG (mmol/L) 1.50 [1.1; 1.9] 
* Wilcoxon matched pairs test. Represents median levels and interquartcombination therapy group. Combination therapy with sim-
vastatin 20 and 40 mg/day led to the same reduction of Lp-
PLA2 mass level by 45%. During combination therapy with
increasing doses of simvastatin from 20 mg up to 40 mg/day,
the level of total cholesterol decreased by 33% and 37%,
respectively, and the level of LDL cholesterol decreased by 49%
and 50%, respectively. Thus, the dose–response effect of
combined therapy with simvastatin and ezetimibe on Lp-PLA2
mass level and lipid proﬁle (total cholesterol, LDL cholesterol)
has not been identiﬁed.
Effect of simvastatin monotherapy on lipid proﬁle and Lp-
PLA2 mass level, according to the simvastatin doses
After treatment it was found that the maximum reduction in
Lp-PLA2 mass level by 49% (up to 207 ng/ml) was recorded
during therapy with simvastatin 80 mg/day, and minimum
reduction in Lp-PLA2 mass level by 29% (up to 220 ng/ml) was
recorded during therapy with simvastatin 40 mg/day. The
maximum decrease by 37% in total cholesterol and by 45% in
LDL-C were recorded in the simvastatin 80 mg/day. In group
therapy with simvastatin 40 mg/day, total cholesterol and
LDL-C reduction were 26% and 39%, respectively. Thus,
simvastatin monotherapy revealed signiﬁcant dose-depen-
dent effect: monotherapy with simvastatin 80 mg/day was
more effective in reducing the Lp-PLA2 mass level and lipid
proﬁle (total cholesterol and LDL-C) than monotherapy with
simvastatin 40 mg/day (P < 0.05). Signiﬁcant differences on the
effect of different doses of simvastatin on HDL-C and TG have
not been identiﬁed (Fig. 2).
Comparison of two tactics lipid-lowering therapy
When comparing combination therapy with simvastatin and
ezetimibe and monotherapy with simvastatin, the following
results were obtained.sterol levels and inflammatory markers.
Posttreatment P* D%
213.08 [192.2; 235.3] <0.001 38
0.69 [0.29; 2.0] <0.001 48
4.01 [3.7; 4.3] <0.001 28
2.19 [2.1; 2.4] <0.001 40
1.15 [0.9; 1.3] 0.016 8
1.12 [0.9; 1.7] 0.002 17
ile range.
Fig. 2 – Bar graphs illustrating compared effects of combination therapy with simvastatin + ezetimibe and monotherapy with
simvastatin on lipid profile and Lp-PLA2 mass level, according to the simvastatin doses included in the combination. Mann–
Whitney U test. P < 0.001 versus baseline for all subgroups. P > 0.05 when comparison between subgroups simvastatin
20 mg + ezetimibe 10 mg and simvastatin 40 mg + ezetimibe 10 mg. P < 0.05 when comparison between subgroups
simvastatin 40 mg and simvastatin 80 mg. P < 0.05 when comparison between subgroups simvastatin 20 mg + ezetimibe
10 mg and simvastatin 40 mg. P > 0.05 when comparison between subgroups simvastatin 20 mg + ezetimibe 10 mg and
simvastatin 80 mg.
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signiﬁcantly greater reductions in levels of Lp-PLA2, total
cholesterol and LDL-C than simvastatin monotherapy 40 mg/
day. Lp-PLA2 mass level decreased by 45% in the combination
therapy group (from 387.17 ng/ml to 204.5 ng/ml) versus 29% in
the monotherapy group (from 319.76 ng/ml to 220.3 ng/ml,
P = 0.003). Total cholesterol decreased in the combination
therapy with simvastatin 20 mg/day by 33% (from 5.84 mmol/L
to 3.84 mmol/L) versus 26% in the monotherapy group with
simvastatin 40 mg/day (from 5.36 mmol/L to 3.99 mmol/L,
P = 0.001). LDL-C level in the combination therapy with
simvastatin 20 mg/day decreased by 50% (from 3.86 mmol/L
to 2.1 mmol/L) versus 39% (from 3 25 mmol/L to 2.16 mmol/L)
in monotherapy with simvastatin 40 mg/day (P < 0.001).
When comparing the initial dose of simvastatin 20 mg/day
in the combination therapy group with a maximum dose of
simvastatin 80 mg/day in the monotherapy group, statistically
signiﬁcant differences in the effects of drugs on the Lp-PLA2
mass level and LDL-C disappeared (P > 0.05). Monotherapy
with simvastatin 80 mg/day led to a greater reduction in total
cholesterol in comparison with combination therapy with
simvastatin 20 mg/day: 37% (from 6.11 mmol/L to 4.19 mmol/
L) versus 33% (from 5.84 mmol/L to 3.84 mmol/L), respectively
(P = 0.03).
When comparing the average dose of simvastatin (40 mg/
day) in combination therapy group and monotherapy group,
the following results were obtained. Combined therapy with
simvastatin 40 mg/day showed signiﬁcantly greater reduc-
tions in Lp-PLA2 mass level, total cholesterol and LDL-C, thanmonotherapy with simvastatin 40 mg/day. Lp-PLA2 mass level
decreased by 45% in the combination therapy group (from
306.41 ng/ml to 189.64 ng/ml) versus 29% (from 319.76 ng/ml to
220.3 ng/ml) in the monotherapy group (P = 0.03).
Total cholesterol decreased in the combination therapy
with simvastatin 40 mg/day by 37% (from 6.17 mmol/L to
3.74 mmol/L) versus 26% (from 5.36 mmol/L to 3.99 mmol/L) in
the monotherapy group with simvastatin 40 mg/day
(P = 0.003). LDL-C level in the combination therapy with
simvastatin 40 mg/day decreased by 50% (from 4.29 mmol/L
to 2.18 mmol/L) versus 39% (from 3.25 mmol/L to 2.16 mmol/L)
in the monotherapy group with simvastatin 40 mg/day
(P = 0.002). When comparing the impact of combination
therapy with simvastatin 40 mg/day and monotherapy with
simvastatin 80 mg/day on lipid proﬁle and Lp-PLA2 mass level
signiﬁcant differences between the two groups were not
found. There was a signiﬁcant correlation between baseline
levels of Lp-PLA2 and total cholesterol (r = 0.28), LDL choles-
terol (r = 0.33) (Fig. 2).
Discussion
Because most of the studies identiﬁed the relationship
between elevated level of Lp-PLA2 and the risk of cardiovas-
cular complications [37–45], the possibility of reducing this
marker has been actively studied. However, according to the
trials, darapladib did not improve cardiovascular outcomes in
patients with coronary artery disease, when added to standard
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also able to signiﬁcantly reduce Lp-PLA2 mass and activity
[22–35]. This can be seen as they pleiotropic effect. Conducting
further reduce Lp-PLA2 by darapladib, did not lead to further
reduction of the risk of coronary events.
The results of our studies have shown that statin therapy,
in addition to lipid-lowering effect, led to a signiﬁcant
reduction of Lp-PLA2 mass level in patients with coronary
artery disease.
Hypolipidemic effect and the reduction of Lp-PLA2 mass
level were more pronounced in the combination therapy with
simvastatin and ezetimibe compared with simvastatin mono-
therapy. For example, in the combination therapy group Lp-
PLA2 mass level reduced by 45% versus 38% in the mono-
therapy group, the reduction in total cholesterol was 35%
versus 28%, and LDL-C reduced by 50% versus 40%, respective-
ly. It was shown that the maximum decrease in Lp-PLA2 mass
level was achieved already at the initial dose of the
simvastatin in the combination therapy and dose–response
effect has not been obtained. Initial dose of the combination
therapy is comparable in efﬁciency with a maximum dose of
simvastatin in monotherapy.
In studies that assessed the effect of statins on the Lp-PLA2
mass level, the following results were obtained. Clinically it was
shown that statins pravastatin [23], atorvastatin [24,32], simva-
statin [25,31] and rosuvastatin [27,33] have signiﬁcantly reduced
Lp-PLA2 mass level at 22–36%. The maximum reduction of
Lp-PLA2 mass level was shown in the MIRACLE study with
atorvastatin monotherapy 80 mg/day in which decrease of
Lp-PLA2 was 35.8% [32]. JUPITER study has shown on 8901
patients that treatment with rosuvastatin 20 mg/day led to the
Lp-PLA2 mass level reduction on 33.8% [33]. According to the
work of Schaefer et al. monotherapy with atorvastatin 40 mg/
day lowered the Lp-PLA2 mass level by 26% [24]. Simvastatin
monotherapy 40 mg/day reduced the Lp-PLA2 mass level on
27% according to the Heart Protection Study [31].
On the effect of statins on LDL-C, our work is consistent with
the data of world literature, but to inﬂuence the Lp-PLA2 mass
level results diverged in our work has revealed more signiﬁcant
reduction in Lp-PLA2 mass level as a monotherapy, and in
combined therapy. We supposed that this result is due to the
fact that our patients had higher Lp-PLA2 mass level baseline.
Patients from the above studies had lower Lp-PLA2 mass
level; it rarely exceeded 320 ng/ml. Conﬁrming our hypothesis,
we found in the work of Muhlestein et al., where it was shown
that anti-inﬂammatory effects of simvastatin depend on the
degree of increase of inﬂammatory markers at baseline.
Simvastatin 20 mg/day reduced Lp-PLA2 mass level by
34.5%, LDL-C by 34% and hs-CRP by 16% in a group of 100
patients with type 2 diabetes and hyperlipidemia. In the
subgroup of patients with a median of Lp-PLA2 mass level
320.9 ng/ml and more or hs-CRP levels> 2 mg/dl, a signiﬁcantly
greater reduction in inﬂammatory markers was found. During
the therapy with simvastatin 20 mg/day Lp-PLA2 mass level
decreased by 47.5%, and hs-CRP level by 24.8% [34].
In the course of combination therapy with simvastatin and
ezetimibe dose-dependent effect on Lp-PLA2 mass level and
lipid proﬁle (total cholesterol, LDL-C) has not been identiﬁed,
while in simvastatin monotherapy, reliable dose-dependent
effect of the drug was detected on the lipid proﬁle (totalcholesterol, LDL-C), and also on its effect on Lp-PLA2 mass
level (P < 0.05).
In addition, IMPROVE-IT study has showed that combina-
tion therapy with simvastatin and ezetimibe has similar
coronary event reduction efﬁcacy as simvastatin monother-
apy [48]. Combination therapy achieves target level of LDL-C
using signiﬁcantly lower doses of statins. This can be
important in elderly patients, in patients with an increased
risk of adverse events and in patients with non-alcoholic liver
disease or isolated elevation of liver transaminases.
Comparison of the two groups can be considered correct, as
both groups started with the same dose of simvastatin of
20 mg/day and increasing the dose depended on achieving the
target level of LDL-C in each patient. The ability to reduce Lp-
PLA2 mass level was determined on the background of the
main lipid-lowering effects of drugs. Dose titration was
performed in accordance with clinical practice. Titration of
dose statin taken in many studies in recent years, for example
IMPROVE-it study. The later comparisons between subgroups
(the population of which is at least 10 patients) do not
contradict the rules of statistical analysis.
In conclusion the present study demonstrates that the
combined treatment, using half the dose of simvastatin, led to
greater reduction of Lp-PLA2 mass level, total cholesterol and
LDL-C, compared to monotherapy with simvastatin. Due to the
steady decline of target levels of LDL-C, which leads to
prescribing high doses of statins (and it is not always possible
because of the presence of co-morbidities), combination
therapy with statin and ezetimibe is a reliable alternative,
which allows not only to largely reduce LDL-C but also to
signiﬁcantly reduce such important participants of atheroscle-
rosis process and markers of inﬂammation, as Lp-PLA2 and CRP.
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